November 22nd 2024
A new study shows that COVID-19 infection significantly increases the risk of exacerbation in patients with myasthenia gravis (MG).
Familial Hypercholesterolemia May Double Coronary Heart Disease Risk in Moderately Elevated LDL-C
January 31st 2024However, the association between familial hypercholesterolemia variants and coronary heart disease slightly weakened after adjusting for baseline low-density lipoprotein cholesterol (LDL-C) level and became statistically insignificant after adjusting for cumulative past LDL-C exposure.
Read More
Health Discrepancies in Criminal Justice System Intrinsically Tied to Public Health
January 31st 2024Research on the state of health care, health outcomes, and health inequities in the criminal justice system continually advocates for structural-level reform and the recognition that carceral health issues are in fact public health issues.
Read More
IV Methylprednisolone, Tacrolimus Effective in Prednisone-Resistant Ocular MG
January 31st 2024Researchers have retrospectively analyzed data from nearly 60 patients with ocular myasthenia gravis (MG) not adequately responding to oral prednisone, finding that both intravenous (IV) methylprednisolone and tacrolimus monotherapy helped reduce symptoms.
Read More
Best Practices That Target Selinexor Treatment Improve MM-Related Outcomes
January 29th 2024Patient survival and such treatment-related outcomes as time to treatment failure and treatment duration improved following implementation of a best practices program that focused on selinexor administration for multiple myeloma (MM), with implications for other anticancer medications.
Read More
ELN Risk Category, MRD Status Predictive of Relapse in Patients With AML
January 29th 2024The study may help explain why some patients are more prone to relapse following a complete response to induction therapy, as indicated by measurable residual disease (MRD) status and 2017 European LeukemiaNet (ELN) criteria.
Read More
Meta-Analysis Investigates Individual Components of CBT for Insomnia
January 29th 2024A meta-analysis explored the individual components of cognitive behavioral therapy for insomnia (CBT-I) and suggested that cognitive restructuring, stimulus control and sleep restrictions provide the more benefits to patients.
Read More
Myeloid Panel Analysis Imperative for Risk Assessment in Patients With CCUS
January 29th 2024A myeloid panel mutation analysis should be prioritized for patients with clonal cytopenia of undetermined significance (CCUS) as it can better assess patient risks for progression to a myeloid malignancy, a recent study argues.
Read More
Low Muscle Mass, Hypoalbuminemia Increase Mortality Risk in ADHF
January 28th 2024Patients admitted to the hospital with acute decompensated heart failure (ADHF) who also had low muscle mass and hypoalbuminemia experienced a heightened mortality risk, suggesting skeletal muscle mass and serum albumin are important prognostic factors.
Read More
Health Equity and Access Weekly Roundup: January 27, 2024
January 27th 2024The Center on Health Equity and Access delivers current updates, highlights breakthroughs in research, and ongoing endeavors committed to addressing healthcare inequalities and improving universal access to exceptional health care.
Read More
Contributor: It’s About Time to Realize the Full Potential of Data in Health Care
January 26th 2024Promoting health equity isn’t only about consideration of underlying health risks; it’s also about using that data to inform population care as well as give clinicians and their teams more time with the patient in front of them.
Read More
Female Patients Less Likely to Receive Guideline-Directed HFrEF Therapies vs Males
January 25th 2024A recent study found that use of optimal guideline-directed medical therapies after heart failure with reduced ejection fraction (HFrEF) diagnosis is low overall, but especially among female patients compared with male patients.
Read More
DMD Guidance Could Benefit From Update, Experts Say
January 24th 2024MEDLINE, the Turning Research Into Practice database, Google Scholar, and organization guidelines were searched for their ongoing applicability to the management of Duchenne muscular dystrophy (DMD) and to determine if there is a need to develop new treatment recommendations.
Read More
Extended Study Shows Consistent Safety, Efficacy in Complex Mental Health Treatment
January 24th 2024Topline results from a pivotal phase 3, open-label extension study showcase the long-term safety and efficacy of olanzapine and samidorphan (Lybalvi) in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder.
Read More
Similar Risk of Death Between Patients With HFimpEF, LVEF Above 40% in DELIVER Trial
January 24th 2024An analysis of the DELIVER trial also revealed an association between dapagliflozin treatment and reduced risk of cardiovascular death among individuals with heart failure with improved ejection fraction (HFimpEF).
Read More
Sacituzumab Govitecan Monotherapy for NSCLC Disappoints in EVOKE-01 Trial Update
January 23rd 2024The TROP-2–directed antibody drug conjugate is currently being investigated as a monotherapy and a combination therapy for non–small cell lung cancer (NSCLC) in 3 trials: phase 3 EVOKE-01, phase 2 EVOKE-02, and phase 3 EVOKE-03.
Read More
Study Highlights Need for Additional Caregiver Support in Higher-Risk MDS
January 23rd 2024The study, which pulled self-reported data from online bulletin boards across the US, Canada, and the United Kingdom in 2020, found that the degree of burden varied based on patient disease stage, among other factors.
Read More